首页> 外文期刊>Chimie Nouvelle >Design, Synthesis and Biological Activity of Therapeutics Targeting The Pi3k Pathway
【24h】

Design, Synthesis and Biological Activity of Therapeutics Targeting The Pi3k Pathway

机译:针对Pi3k途径的药物的设计,合成和生物活性

获取原文
获取原文并翻译 | 示例
           

摘要

The phosphatidylinositol-3-kinase/protein kinase B (PDK/ PKB) signaling pathway —also known as the survival or anti-apoptotic pathway— plays an important role in controlling cell growth, proliferation and survival. Whatever the mechanism, the prevalence of PI3K/PKB signaling abnormalities in human cancers and its potential biological effects (e.g., competitive growth advantage, evasion from apoptosis and therapy resistance) has suggested the potential use of PI3K/PKB pathway modulators as novel targeted therapeutic agents in oncology. Following this strategy, a number of compounds have demonstrated antitumour activity in preclinical and clinical settings by targeting directly or indirectly the different components of this pathway. This oral presentation will detail our structure-based design efforts to identify modulators of PDK1 and PI3K, and will highlight the evolution of our targeted therapeutic strategies for the PI3K/ PKB survival pathway.
机译:磷脂酰肌醇-3-激酶/蛋白激酶B(PDK / PKB)信号传导途径(也称为存活或抗凋亡途径)在控制细胞生长,增殖和存活中起着重要作用。无论采用哪种机制,PI3K / PKB信号异常在人类癌症中的普遍性及其潜在的生物学效应(例如竞争性增长优势,逃避凋亡和治疗耐药性)表明,PI3K / PKB途径调节剂可作为新型靶向治疗剂在肿瘤学上。遵循该策略,许多化合物通过直接或间接靶向该途径的不同成分,在临床前和临床环境中显示出抗肿瘤活性。这次口头报告将详细介绍我们基于结构的设计工作,以鉴定PDK1和PI3K的调节剂,并将重点介绍PI3K / PKB生存途径的靶向治疗策略的演变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号